Rivernorth Capital Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Rivernorth Capital Management’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-250,000	Closed	-$28.6K	–	408
2024 Q4	$28.6K	Hold	250,000	–	–	﹤0.01%	274
2024 Q3	$26.1K	Hold	250,000	–	–	﹤0.01%	243
2024 Q2	$25K	Hold	250,000	–	–	﹤0.01%	282
2024 Q1	$35K	Hold	250,000	–	–	﹤0.01%	275
2023 Q4	$35K	Hold	250,000	–	–	﹤0.01%	266
2023 Q3	$57.5K	Hold	250,000	–	–	﹤0.01%	290
2023 Q2	$47.5K	Buy	+250,000	New	+$43.5K	﹤0.01%	312

Rivernorth Capital Management's BLACR Position: Q1 2025 in Review

Rivernorth Capital Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 250,000 shares — an estimated $28.6K sold.

Rivernorth Capital Management first reported a position in BLACR in Q2 2023 and held it in 7 quarters. The position peaked at $57.5K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Rivernorth Capital Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Rivernorth Capital Management sold 250,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $28.6K.
Rivernorth Capital Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and held it in 7 quarters.
Rivernorth Capital Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $57.5K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Rivernorth Capital Management's 13F filing for Q1 2025, filed 15 May 2025.